SCHEMBL5458510

SCHEMBL5458510

CN1CCc2cc(N(C)C)c(S(=O)(=O)c3ccc(Cc4ccccc4C#N)cc3)cc2CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.36
DRD2 P14416 4/20 0.35
DRD3 P35462 3/20 0.35
HTR2A P28223 3/20 0.34
HTR2C P28335 3/20 0.34
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KCNH2 Q12809 2/20 0.33
PARG Q86W56 1/20 0.33
HSD11B1 P28845 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
TAS2R14 Q9NYV8 2/20 0.33
KCNJ1 P48048 1/20 0.33
CA2 P00918 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
DPP4 P27487 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457179 0.88 HTR6 (0.38) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL5450607 0.88 HTR2A (0.37) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL5453940 0.86 HTR6 (0.37) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL5448785 0.86 TP53 (0.38) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL5458561 0.86 HTR6 (0.45) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL14411990 0.85 HTR6 (0.43) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL5450670 0.84 SIGMAR1 (0.40) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL5455500 0.83 KCNJ1 (0.38) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL5450652 0.83 USP2 (0.36) HTR6DRD2DRD3HTR2AHTR2C
SCHEMBL5450675 0.83 KCNH2 (0.39) HTR6DRD2DRD3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP claimed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 HTR6 166/4885DRD2 46/4885DRD3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.